1. Apremilast and biologics: Characteristics of patients treated with apremilast before, during, or after a biological treatment
- Author
-
Elena Lucia Pinto‐Pulido, Ana Rodríguez‐Villa Lario, David Vega‐Díez, Marta González‐Cañete, Elena García‐Verdú, Isabel Polo‐Rodríguez, Ana Belén Piteiro‐Bermejo, Susana Medina‐Montalvo, and Lidia Trasobares‐Marugán
- Subjects
Biological Products ,Anti-Inflammatory Agents, Non-Steroidal ,Arthritis, Psoriatic ,Humans ,Psoriasis ,Dermatology ,General Medicine ,Thalidomide - Abstract
Apremilast is an oral small molecule approved for the treatment of psoriasis, psoriatic arthritis and oral ulcers associated with Behçet's disease. This research was conducted to describe the characteristics of patients who received treatment with apremilast for a skin disorder, either before, during, or after a biological treatment, with the aim of analyze the reasons that lead to start this drug in real clinical practice or suspend it for another. A total of 41 patients were enrolled: nine (22.0%) had received biological treatment prior to apremilast, seven (17.0%) both before and after apremilast and 25 (61.0%) after apremilast. One patient received concomitant treatment with adalimumab and apremilast. Most patients (85.4%) received apremilast as treatment for psoriasis. Reasons for starting apremilast were lack of efficacy with previous treatments (85.4%) and adverse effects or contraindication to previous treatments (14.6%), without statistically significant differences between patients who had received a previous biologic and those who had not. Drug survival was not influenced by previous biological treatment, but we found an increased risk of drug discontinuation in patients with chronic kidney disease (log-rank p = 0.028). The main reason of apremilast withdrawal was lack of adequate disease control (60.0%), most of whom required treatment with biologics. Therefore, despite the extensive development of new therapies for psoriasis and other dermatological conditions, apremilast is a widely used drug even in patients who are candidates for biologic treatment. Its initiation is more frequent due to poor disease control than because of other therapies contraindications.
- Published
- 2022